The effect of oral L-carnitine supplementation on polycystic ovary syndrome

Comparison of the effect of oral L-carnitine and placebo supplementation on anthropometric indices, lipid status, insulin and hormone resistance indices in obese / overweight women suffering from polycystic ovary syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191016045131N1

Enrollment

Registered

2019-12-30

Start date

2019-10-21

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome. Polycystic Ovarian Syndrome

Interventions

Intervention 1: Control group: receiving placebo containing non-active substance for 12 weeks. Intervention 2: Intervention group: Oral administration of L-carnitine supplement 1000 mg daily for 12 we

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 18-45 years old women referred to Yazd Diabetes Center Polycystic ovary syndrome based on Rotterdam diagnostic criteria Body Mass Index 25 and over interested in participation in the study Taking usual treatment of PCOS

Exclusion criteria

Exclusion criteria: Smoking Suffering from diabetes or thyroid disease Having a special diet for the past three months Weight-loss medication, hormone or ovulation stimulant use

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Insulin Kit.;Fasting blood sugar. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;Sex hormone-binding globulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: kit.;Triglyceride. Timepoint: At the beginning and at the end of the study (120 days after). Method of measurement: Blood test.;Cholesterol. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;HDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;LDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;HOMA IR. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: By formula using fasting glucose and insulin.	—

Measure

Time frame

Insulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Insulin Kit.;Fasting blood sugar. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;Sex hormone-binding globulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: kit.;Triglyceride. Timepoint: At the beginning and at the end of the study (120 days after). Method of measurement: Blood test.;Cholesterol. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;HDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;LDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;HOMA IR. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: By formula using fasting glucose and insulin.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Pakravanfar

Yazd University of Medical Sciences

fatemeh.p1993@yahoo.com+98 31 5557 3812

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 21, 2026